ACAna Paula Beltran Moschione Castro

Ana Paula Beltran Moschione Castro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Paula Beltran Moschione Castro has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Insights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy

    by Lais Ferreira Lopes Brum, Nayara Maria Furquim Nasser, Glauce Hiromi Yonamine, Thais Costa Lima de Moura, Mayra de Barros Dorna, Antonio Carlos Pastorino, Beni Morgenstern, Ana Paula Moschione Castro

  • Open Access

    Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study

    by Mariele Morandin Lopes, Ana Paula Moschione Castro, Túlio Morandin Ferrisse, Jorge Kalil, Ariana Campos Yang, Fabio Morato Castro

    The objective of this study performed in Brazil was to understand the real-life efficacy and safety of using dupilumab in patients with moderate or severe atopic dermatitis.

  • Open Access

    Understanding the natural history of selective IgA deficiency

    by Nayara Maria Furquim Nasser, Antonio Carlos Pastorino, Thais Costa Lima de Moura, Beni Morgenstern, Mayra de Barros Dorna, Ana Paula Beltran Moschione Castro


  • The importance of follow‐up of esophageal eosinophilia in children with severe cow's milk allergy

    by Bruna Pultrini Aquilante, Rosely Antunes Patzina, Silvia Regina Cardoso, Antonio Carlos Pastorino, Ricardo Katsuya Toma, Glauce Hiromi Yonamine, Mayra de Barros Dorna, Ana Paula Beltran Moschione Castro

  • Impaired bone mineral density and microarchitecture in female adolescents with IgE-mediated cow’s milk allergy

    by Glauce Hiromi Yonamine, Diogo Souza Domiciano, Liliam Takayama, Ana Paula Beltran Moschione Castro, Rosa Maria Rodrigues Pereira, Antonio Carlos Pastorino

    Summary This study compared the bone parameters of adolescents with persistent cow’s milk allergy (CMA) with those of healthy adolescents. Adolescents with CMA had compromised bone parameters (lower bone mineral density, impaired trabecular microarchitecture, and lower bone strength). Partial exclusion diet was associated with better bone parameters than total exclusion diet. Background Persistent immunoglobulin E (IgE)–mediated cow’s milk allergy (CMA) may impair bone parameters and increase the risk of fractures. High-resolution peripheral quantitative computed tomography (HR-pQCT) is a novel methodology that not only assesses trabecular and cortical bone compartments and volumetric density measurements, but also evaluates bone microarchitecture and estimates biomechanical properties through finite element analysis (FEA). Both HR-pQCT and bone strength parameters derived from FEA have shown a strong correlation with fracture risk. Purpose To assess the bone density, microarchitecture, and bone strength of adolescents with persistent IgE-mediated CMA (IgE-CMA). Methods This was an observational, cross-sectional study with female adolescents with persistent IgE-CMA and healthy control participants matched by female sex and sexual maturation. Bone parameters were assessed by areal bone mineral density (aBMD) through dual-energy X-ray absorptiometry (DXA), bone microarchitecture by HR-pQCT at the radius and tibia, and laboratory markers related to bone metabolism. Results The median age of adolescents with persistent IgE-CMA (n = 26) was 13.0 years (interquartile range (IQR) 11.4–14.7) and of healthy control participants (n = 28) was 13.6 years (IQR 11.9–14.9). Adolescents with IgE-CMA ingested 27.4% less calcium (p = 0.012) and 28.8% less phosphorus (p = 0.009) than controls. Adolescents with IgE-CMA had lower bone mineral content (BMC) (38.83 g vs. 44.50 g) and aBMD (0.796 g/cm2 vs. 0.872 g/cm2) at lumbar spine, and lower BMC (1.11 kg vs. 1.27 kg) and aBMD (0.823 g/cm2 vs. 0.877 g/cm2) at total body less head (TBLH) (p < 0.05). However, Z-scores BMC and Z-scores aBMD at lumbar spine and TBLH, when adjusted for Z-score height/age, were not significantly different between the groups. Moreover, CMA adolescents had lower bone strength at the distal tibia (S 169 kN/mm vs. 194 kN/mm; F Load 8030 N vs. 9223 N) (p < 0.05). Pairing of groups by the presence of menarche showed compromised parameters at the tibia—lower total volumetric BMD (Tt.vBMD) (293.9 mg HA/cm3 vs. 325.9 mg HA/cm3) and trabecular vBMD (Tb.vBMD) (170.8 mg HA/cm3 vs. 192.2 mg HA/cm3), along with lower cortical thickness (Ct.th) (1.02 mm vs. 1.16 mm) and bone strength (S 174 kN vs. 210 kN; F Load 8301 N vs. 9950 N)—and at the radius (S 61 kN/mm vs. 71 kN/mm; F Load 2920 N vs. 3398 N) (p < 0.05) among adolescents with IgE-CMA. Adolescents with IgE-CMA on a total exclusion diet (n = 12) showed greater impairment of bone features than those on a partial exclusion diet (n = 14), with lower lumbar spine Z-score BMC (− 0.65 vs. 0.18; p = 0.013), lumbar spine trabecular bone score (TBS) (1.268 vs. 1.383; p = 0.005), Z-score TBS (0.03 vs. 1.14; p = 0.020), TBLH Z-score BMC (− 1.17 vs. − 0.35; p = 0.012), TBLH Z-score aBMD (− 1.13 vs. − 0.33; p = 0.027), Tt.vBMD at the tibia (259.0 mg HA/cm3 vs. 298.7 mg HA/cm3; p = 0.021), Ct.th at the tibia (0.77 mm vs. 1.04 mm; p = 0.015) and Ct.th at the radius (0.16 mm vs. 0.56 mm; p = 0.033). Conclusion Adolescents with persistent IgE-CMA had lower aBMD and compromised microarchitecture (impaired trabecular microarchitecture and lower bone strength). Adolescents on a partial exclusion diet had better bone parameters than those on a total exclusion diet.


  • Open Access

    Fenotipos y endotipos en alergia alimentaria

    by Ana Paula Beltrán Moschione Castro, Maria Belen Bossio

    La alergia alimentaria es un evento frecuente, especialmente en la población pediátrica, que afecta entre el 3-6% de los niños. Existen diversos desafíos en el cuidado de los pacientes con alergia alimentaria, pero ciertamente la diversidad de los síntomas y el desenlace de la enfermedad son aspectos importantes en el tratamiento de los pacientes, en la elaboración de las pautas de cuidado y en el conocimiento de la historia natural de la enfermedad. La clasificación en fenotipos permite una mejor comprensión de la evolución de la alergia alimentaria. El endotipo es un subtipo de un fenotipo definido por su característica fisiopatológica. Las características genéticas, epigenéticas y ambientales interfieren en la construcción del fenotipo y sus posibles endotipos. Entender los fenotipos y endotipos de las alergias alimentarias trae consigo dos aspectos fundamentales: 1) la necesidad de entender que el análisis de fenotipos y endotipos en alergia alimentaria permitirá establecer pronósticos y ayudar en la intervención con terapias específicas, y 2) la importancia de comprender la caracterización de los endotipos y fenotipos locales, y la diversidad alimentaria de los diferentes países que conforman América Latina trae consigo un variado menú de alimentos que puede suponer un riesgo de alergia que es necesario estudiar.

  • Open Access

    Idiopathic musculoskeletal pain, musculoskeletal pain syndromes, and use of electronic devices in adolescents with asthma

    by Mariana Machado Forti Nastri, Benito Lourenço, Ligia Bruni Queiroz, Luiz Eduardo Vargas da Silva, Daniela Mencaroni Rodrigues Lourenço, Ana Paula Beltran Moschione Castro, Clovis Artur Silva, Antonio Carlos Pastorino


  • Inflammatory manifestations in children with chronic granulomatous disease

    by Myris Satiko Shinzato Tatebe, Mayra de Barros Dorna, Ana Paula Beltran Moschione Castro, Antonio Carlos Pastorino

    Click on the article title to read more.


  • Open Access

    Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient

    by José Roberto Mendes Pegler, Ana Paula Beltran Moschione Castro, Antonio Carlos Pastorino, Mayra de Barros Dorna

    Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions [...] ABSTRACT Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions

  • Open Access

    Neutropenia in antibody‐deficient patients under IVIG replacement therapy

    by Sonia Lemos, Cristina M. A. Jacob, Antonio C. Pastorino, Ana Paula B. M. Castro, Ângela B. F. Fomin, Magda M. S. Carneiro‐Sampaio

    Patients with antibody deficiencies are more prone to develop acute neutropenic episodes even during immunoglobulin replacement. The aims of this study were to evaluate the presence of acute neutropenia in 42 patients with primary antibody immunodeficiencies, currently receiving intravenous immunoglobulin (IVIG), and to describe the clinical and laboratory findings during neutropenic episodes. Of all patients, 10 (23.8%) presented acute neutropenia (absolute neutrophil count 3) during follow up (mean of 6.4 yr). The absolute neutrophil count ranged from 71 to 1488 cells/mm3. Neutropenia was not clearly associated with antibiotic prophylactic therapy or immunoglobulin levels, while infections were associated with neutropenia in the majority of episodes. Most acute neutropenia episodes were mild or moderate, except in CVID patients who present more severe neutropenia. Although IVIG may have contributed to reducing the severity of neutropenia, it does not prevent its occurrence in all patients. In conclusion, primary immunodeficient patients, even submitted to IVIG replacement therapy, must be regularly evaluated for neutropenia in order to minimize the risk of infections and its appropriate approach.